Education
About Us
Working with TipRanks
Follow Us
Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
COYA Stock Chart & Stats
$5.30
-$0.10(-1.62%)
At close: 4:00 PM EST
$5.30
-$0.10(-1.62%)
Day’s Range― - ―
52-Week Range$4.65 - $8.29
Previous CloseN/A
Volume16.99K
Average Volume (3M)185.62K
Market Cap
$114.88M
Enterprise Value$67.25M
Total Cash (Recent Filing)$28.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 24, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding20,924,456
10 Day Avg. Volume237,515
30 Day Avg. Volume185,623
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)2.21
Price to Sales (P/S)24.57
P/FCF Ratio-8.49
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue16.86
Enterprise Value/Gross Profit-21.16
Enterprise Value/Ebitda-3.37
Forecast
1Y Price Target
$17.75Price Target Upside234.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ALSTARS Phase 2 trial starts patient dosing to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS).
Financial PerformanceCoya Therapeutics recently completed an equity financing that comprised the sale of ~4.2M shares of common stock at a price of $5.50 per share, resulting in total gross proceeds of $23M.
Milestone PaymentsThe initiation of patient dosing in the ALSTARS trial is slated to trigger the payment of a $4.2M milestone from Coya's partner, Dr. Reddy's Laboratories.
Bears Say
Commercial RisksRisks include poorer than anticipated commercial uptake.
Financial RisksRisks include possible medium-term dilution risk.
Regulatory RisksRisks include clinical setbacks involving COYA 302, inability to advance into pivotal development, and failure to secure U.S. regulatory approval.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $4.65 and its highest was $8.29 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Coya Therapeutics, Inc.’s market cap is $114.88M.
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is Mar 24, 2026 which is in 94 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on Sep 30, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.233 by $0.103.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.28.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 20,924,456 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.233. Following the earnings report the stock price went up 0.707%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coya Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.75 (234.91% Upside)
$17.75 (234.91% Upside)
Blogger Sentiment
Bullish
COYA Sentiment 100%
Sector Average 68%
Sector Average 68%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.72%
12-Months-Change
Fundamentals
Return on Equity
-62.18%
Trailing 12-Months
Asset Growth
-9.87%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. (COYA) is a biotechnology company focused on developing innovative therapies for neurodegenerative and autoimmune diseases. The company leverages its expertise in regulatory T-cell (Treg) technology to create treatments that address the underlying causes of these conditions. Coya's core products are designed to modulate the immune system to enhance the body's natural ability to combat disease, offering new hope for patients with limited treatment options.
COYA Stock 12 Month Forecast
Average Price Target
$17.75
▲(234.91% Upside)
Technical Analysis
Ownership Overview
4.95% Insiders
4.69% Mutual Funds
15.82% Other Institutional Investors
70.93% Public Companies and
Individual Investors